Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection would significantly reduce the global burden of disease associated with chronic HCV infection. <...
Main Authors: | Swadling, L, Halliday, J, Kelly, C, Brown, A, Capone, S, Ansari, M, Bonsall, D, Richardson, R, Hartnell, F, Collier, J, Ammendola, V, Del Sorbo, M, Von Delft, A, Traboni, C, Hill, A, Colloca, S, Nicosia, A, Cortese, R, Klenerman, P, Folgori, A, Barnes, E |
---|---|
Format: | Journal article |
Published: |
MDPI
2016
|
Similar Items
-
Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
by: Swadling, L, et al.
Published: (2016) -
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection
by: Leo Swadling, et al.
Published: (2016-08-01) -
A highly immunogenic novel genetic vaccine against HCV
by: Del Sorbo, M, et al.
Published: (2012) -
IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION
by: Kelly, C, et al.
Published: (2012) -
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)